From the page to the clinic: Implementing new National Asthma Education and Prevention Program guidelines.
The National Asthma Education and Prevention Program's (NAEPP) revised guidelines, the Expert Panel Report 3 (EPR-3), published in 2007, represents a shift in the approach to asthma: the EPR-3 recommends that clinicians think of asthma as a chronic disease with an inflammatory basis. EPR-3 guidelines also represent a shift in the treatment paradigm for asthma in line with the shift in approach: although symptomatic relief is still necessary, the primary goal of asthma treatment is now long-term control, with the aim of minimizing exacerbation frequency and severity and limiting possible permanent airway damage that can result from frequent asthma exacerbations. To help clinicians implement the new EPR-3 guidelines into daily practice, the NAEPP's Guidelines Implementation Panel has identified 6 key action-focused recommendations. This article describes those recommendations and the evidence supporting them.
Rachelefsky
Gary S
GS
Allergy and Immunology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. grachelefsky@mednet.ucla.edu
D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000517:prevention & control*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002908:Chronic Disease; D015897:Comorbidity; D004333:Drug Administration Routes; D004777:Environment; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000517:prevention & control; D010353:Patient Education as Topic / Q000379:methods*; D017410:Practice Guidelines as Topic; D012129:Respiratory Function Tests; D012720:Severity of Illness Index
D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents